Triple meeting 2024 – Aktis radiotherapy heads for the clinic
AKY-1189 could be used in Padcev-relapsed patients, and in cancers beyond bladder.
AKY-1189 could be used in Padcev-relapsed patients, and in cancers beyond bladder.
Mevrometostat is the only EZH2 inhibitor in phase 3 for prostate cancer.
For $850m up front Roche gets to challenge Pfizer.
First-in-human trial initiations reveal four KRAS assets.
Incyte’s first substantial data with INCB123667 are eclipsed by Pfizer’s PF-07104091/atirmociclib combo.
Patients' expression of CEACAM5 might hold the key to activity after all.